相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Yu Fu et al.
ACTA PHARMACEUTICA SINICA B (2020)
A conserved intratumoral regulatory T cell signature Identifies 4-1BB as a pan-cancer target
Zachary T. Freeman et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
Anne Froehlich et al.
EBIOMEDICINE (2020)
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Alireza Labani-Motlagh et al.
FRONTIERS IN IMMUNOLOGY (2020)
Polymorphonuclear myeloid-derived suppressor cells limit antigen cross- presentation by dendritic cells in cancer
Alessio Ugolini et al.
JCI INSIGHT (2020)
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
Ilaria Grazia Zizzari et al.
CANCERS (2020)
IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+T-cells
A. Ugolini et al.
ANNALS OF ONCOLOGY (2020)
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells
Alessio Ugolini et al.
EBIOMEDICINE (2020)
POTENT TUMOR-DIRECTED T CELL ACTIVATION AND IN VIVO TUMOR INHIBITION INDUCED BY A 4-1BB X 5T4 ADAPTIR™ BISPECIFIC ANTIBODY
Michelle Nelson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Principles of adoptive T cell therapy in cancer
Ozcan Met et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343
Marlon J. Hinner et al.
CLINICAL CANCER RESEARCH (2019)
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
Dinh-Toi Chu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Christina Claus et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
Gerald P. Linette et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma
Melanie Boxberg et al.
JOURNAL OF IMMUNOLOGY (2019)
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
Ezra E. W. Cohen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
Inaki Etxeberria et al.
ESMO OPEN (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes
M. Angela Aznar et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2018)
4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
Ashley V. Menk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Ilaria Grazia Zizzari et al.
CANCER IMMUNOLOGY RESEARCH (2018)
T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy
Rikke Andersen et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Mitochondria! Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Alvaro Teijeira et al.
CANCER IMMUNOLOGY RESEARCH (2018)
The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one
M. Nuti et al.
CANCER TREATMENT REVIEWS (2018)
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
Marta Compte et al.
NATURE COMMUNICATIONS (2018)
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
Juan M. Zapata et al.
FRONTIERS IN IMMUNOLOGY (2018)
Role of the immunosuppressive microenvironment in immunotherapy
Garth W. Tormoen et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
Maria Parkhurst et al.
CLINICAL CANCER RESEARCH (2017)
Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation
Sivan Seliktar-Ofir et al.
FRONTIERS IN IMMUNOLOGY (2017)
Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)
M. Sznol et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2017)
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Chunhong Zheng et al.
CELL (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
Rikke Andersen et al.
CLINICAL CANCER RESEARCH (2016)
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy
Alfonso R. Sanchez-Paulete et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tumor infiltrating lymphocytes in ovarian cancer
Phillip P. Santoiemma et al.
CANCER BIOLOGY & THERAPY (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
Atsushi Yonezawa et al.
CLINICAL CANCER RESEARCH (2015)
Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer
Kurt A. Schalper et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer
Kurt A. Schalper et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma
Takumi Kobayashi et al.
ONCOIMMUNOLOGY (2015)
OX40 agonists anc combination immunotherapy: putting the pedal to the metal
Stefanie N. Linch et al.
FRONTIERS IN ONCOLOGY (2015)
A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+NHL.
Ajay K. Gopal et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert
Yuwen Zhu et al.
CLINICAL CANCER RESEARCH (2014)
Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
John R. Webb et al.
CLINICAL CANCER RESEARCH (2014)
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Qunrui Ye et al.
CLINICAL CANCER RESEARCH (2014)
Adoptive immunotherapy for cancer
Marco Ruella et al.
IMMUNOLOGICAL REVIEWS (2014)
Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer
Vanessa Gauttier et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies
Shravan Madireddi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers
Jennifer A. Westwood et al.
LEUKEMIA RESEARCH (2014)
Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice
Jennifer A. Westwood et al.
PLOS ONE (2014)
Localized Immunotherapy via Liposome-Anchored Anti-CD137+IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
Brandon Kwong et al.
CANCER RESEARCH (2013)
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Ignacio Melero et al.
CLINICAL CANCER RESEARCH (2013)
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Ignacio Melero et al.
CLINICAL CANCER RESEARCH (2013)
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
Aizea Morales-Kastresana et al.
CLINICAL CANCER RESEARCH (2013)
Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
Paolo A. Ascierto et al.
CLINICAL CANCER RESEARCH (2013)
Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
Michal J. Besser et al.
CLINICAL CANCER RESEARCH (2013)
Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy
Simon Turcotte et al.
JOURNAL OF IMMUNOLOGY (2013)
Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation
Min Dai et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Zhiqiang Guo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
Jessica Ann Chacon et al.
PLOS ONE (2013)
Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
Huafeng Wei et al.
PLOS ONE (2013)
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
Aizea Morales-Kastresana et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
Shi-Yan Li et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2013)
Oncolytic Virus and Anti-4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer
Liza B. John et al.
CANCER RESEARCH (2012)
Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma
Gulsun Erdag et al.
CANCER RESEARCH (2012)
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
Laszlo G. Radvanyi et al.
CLINICAL CANCER RESEARCH (2012)
Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma
Shari Pilon-Thomas et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
Ester Simeone et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12
Jose I. Quetglas et al.
MOLECULAR THERAPY (2012)
The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy
Asis Palazon et al.
CANCER DISCOVERY (2012)
Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses
Shannon E. Smith et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes
Asis Palazon et al.
CANCER RESEARCH (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Establishment and Large-scale Expansion of Minimally cultured Young Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy
Orit Itzhaki et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
Michael A. Curran et al.
PLOS ONE (2011)
CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells
Hidehiko Narazaki et al.
BLOOD (2010)
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
Michal J. Besser et al.
CLINICAL CANCER RESEARCH (2010)
Immune infiltration in human tumors: a prognostic factor that should not be ignored
F. Pages et al.
ONCOGENE (2010)
Signaling Through OX40 Enhances Antitumor Immunity
Shawn M. Jensen et al.
SEMINARS IN ONCOLOGY (2010)
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Roch Houot et al.
BLOOD (2009)
The significance of OX40 and OX40L to T-cell biology and immune disease
Michael Croft et al.
IMMUNOLOGICAL REVIEWS (2009)
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Young H. Kim et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice
Seong-A Ju et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy
Kazue Watanabe et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb
Betty Li et al.
CLINICAL IMMUNOLOGY (2007)
Mouse dendritic-endothelial cell hybrids and 4-1 BB costimulation elicit antitumor effects mediated by broad Antiangiogenic immunity
Eric Ko et al.
CANCER RESEARCH (2007)
Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities
Matthias Wolfl et al.
BLOOD (2007)
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines
Thomas C. Wehler et al.
BLOOD (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity
Ergun Kocak et al.
CANCER RESEARCH (2006)
Adoptive immunotherapy for cancer: building on success
L Gattinoni et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Tumor-infiltrating T lymphocytes: friends or foes?
P Yu et al.
LABORATORY INVESTIGATION (2006)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes
KO Nam et al.
JOURNAL OF IMMUNOLOGY (2005)
NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation
DP Xu et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo
W Dawicki et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses
J Bukczynski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens
I Tirapu et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-κB(RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen
C Wiethe et al.
JOURNAL OF IMMUNOLOGY (2003)
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
ME Dudley et al.
JOURNAL OF IMMUNOTHERAPY (2003)
Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction
WY Ho et al.
CANCER CELL (2003)
Costimulation of human CD28- T cells by 4-1BB ligand
J Bukczynski et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1
HW Lee et al.
JOURNAL OF IMMUNOLOGY (2002)
Immune responses in 4-1BB (CD137)-deficient mice
BS Kwon et al.
JOURNAL OF IMMUNOLOGY (2002)
In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses
ES Halstead et al.
NATURE IMMUNOLOGY (2002)
4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function
T Wen et al.
JOURNAL OF IMMUNOLOGY (2002)
In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway
L Diehl et al.
JOURNAL OF IMMUNOLOGY (2002)
Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection
EM Bertram et al.
JOURNAL OF IMMUNOLOGY (2002)
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB
MV Maus et al.
NATURE BIOTECHNOLOGY (2002)
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells
T Futagawa et al.
INTERNATIONAL IMMUNOLOGY (2002)
4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy
JL Cannons et al.
JOURNAL OF IMMUNOLOGY (2001)
Phenotypic characterization of five dendritic cell subsets in human tonsils
KL Summers et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation
SH Chen et al.
MOLECULAR THERAPY (2000)
分享论文
